Dianthus Therapeutics, Inc. /DE/
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) Trading Plans. The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the quarter ended June 30, 2026:
| Name (Title) | Action Taken (Date of Action) | Nature of Trading Arrangement | Type of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Edward Carr (Chief Accounting Officer) | Adoption (June 18, 2026) | Sale | Rule 10b5-1 trading arrangement | Through and including June 30, 2027 | Up to 50,000 |
| Marino Garcia (President & Chief Executive Officer) | Adoption (May 8, 2026) | Sale | Rule 10b5-1 trading arrangement | Through and including August 7, 2027 | Up to 200,041 |
| Anne McGeorge(Director) | Adoption (May 11, 2026) | Sale | Rule 10b5-1 trading arrangement | Through and including August 10, 2027 | Up to 13,250 |
| Simon Read (Director) | Adoption (May 8, 2026) | Sale | Rule 10b5-1 trading arrangement | Through and including February 9, 2028 | Up to 16,666 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.